MULTI-RESSISTRY BACTERIAL CO-INFECTIONS AND ANTIBIOTIC PRESCRIPTION PRACTICE IN ADULTS WITH COVID-19: A CASE CONTROL STUDY
DOI:
https://doi.org/10.47820/recima21.v3i8.1814Keywords:
COVID-19, Multi-resistance, AntibioticsAbstract
The emerging situation in health services caused by coronavirus has resulted in a strenuous increase in ICU admissions, as well as the use of antimicrobials, often indicated for treatment of co-infections acquired in the hospital environment. The present study aims to describe the factors associated with bacterial co-infections with a multidrug resistance (MR) profile compared to patients without a multidrug resistance profile. For this purpose, a case-control study was conducted containing 127 patients who were hospitalized with a diagnosis of COVID-19 and admitted to the Intensive Care Unit (ICU) of the reference hospital for the 8th Health Regional of Francisco Beltrão-PR, Brazil, with laboratory and clinical evidence of coinfection. The mean age was 55.22 years, ranging from 24 to 86 years, 85% of patients were admitted in the year 2021, 52.8% were male, stayed an average of 17.72 days in the ICU and 79.5% had at least one comorbidity, especially obesity, diabetes and hypertension. Of 66.1% COVID-19 patients who died, 52.4% had at least one multidrug-resistant bacteria (MR) coinfection. Patients with MR had a greater number of comorbidities, stayed more days in the ICU, used antimicrobials longer, and ventilator-associated pneumonia was variably associated with the presence of MR in patients with COVID-19.
Downloads
References
Farfour E, Lecuru M, Dortet L, Le Guen M, Cerf C, Karnycheff F, et al. Carbapenemase- producing Enterobacterales outbreak: Another dark side of COVID-19. Am J Infect Control. dezembro de 2020;48(12):1533–6.
Cantón R, Gijón D, Ruiz-Garbajosa P. Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic. Curr Opin Crit Care. outubro de 2020;26(5):433–41.
Cultrera R, Barozzi A, Libanore M, Marangoni E, Pora R, Quarta B, et al. Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings. Int J Environ Res Public Health. 20 de abril de 2021;18(8):4358.
Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan). 25 de abril de 2021;13(1):5.
Langford BJ, So M, Raybardhan S, Leung V, Soucy J-PR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. abril de 2021;27(4):520–31.
Bentivegna E, Luciani M, Arcari L, Santino I, Simmaco M, Martelletti P. Reduction of Multidrug-Resistant (MDR) Bacterial Infections during the COVID-19 Pandemic: A Retrospective Study. Int J Environ Res Public Health. 23 de janeiro de 2021;18(3):1003.
Marra AR, Camargo LFA, Pignatari ACC, Sukiennik T, Behar PRP, Medeiros EAS, et al. Nosocomial Bloodstream Infections in Brazilian Hospitals: Analysis of 2,563 Cases from a Prospective Nationwide Surveillance Study▿. J Clin Microbiol. maio de 2011;49(5):1866–71.
Graves N. Economics and Preventing Hospital-acquired Infection. Emerg Infect Dis. abril de 2004;10(4):561–6.
Razzaque MS. Exacerbation of antimicrobial resistance: another casualty of the COVID-19 pandemic? Expert Rev Anti Infect Ther. agosto de 2021;19(8):967–71.
Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 3 de dezembro de 2020;71(9):2459–68.
Cheng LS, Chau SK, Tso EY, Tsang SW, Li IY, Wong BK, et al. Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster. Therapeutic Advances in Infection. 1o de janeiro de 2020;7:2049936120978095.
Knight GM, Glover RE, McQuaid CF, Olaru ID, Gallandat K, Leclerc QJ, et al. Antimicrobial resistance and COVID-19: Intersections and implications. Cooper VS, Perry GH, organizadores. eLife. 16 de fevereiro de 2021;10:e64139.
Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ. 1o de julho de 2020;98(7):442-442ª.
Ramadan HK-A, Mahmoud MA, Aburahma MZ, Elkhawaga AA, El-Mokhtar MA, Sayed IM, et al. Predictors of Severity and Co-Infection Resistance Profile in COVID-19 Patients: First Report from Upper Egypt. Infect Drug Resist. 2020;13:3409–22.
Diaz E, Lorente L, Valles J, Rello J. [Mechanical ventilation associated pneumonia]. Med Intensiva. 1o de junho de 2010;34(5):318–24
Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Azzam Lopez A, Diez-Remesal Y, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis. março de 2021;40(3):495–502.
Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care. 7 de setembro de 2020;10(1):119.
Bogossian EG, Taccone FS, Izzi A, Yin N, Garufi A, Hublet S, et al. The Acquisition of Multidrug-Resistant Bacteria in Patients Admitted to COVID-19 Intensive Care Units: A Monocentric Retrospective Case Control Study. Microorganisms. 19 de novembro de 2020;8(11):E1821.
Vaughn VM, Gandhi TN, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study. Clin Infect Dis. 18 de maio de 2021;72(10):e533–41.
Cole J, Barnard E. The impact of the COVID-19 pandemic on healthcare acquired infections with multidrug resistant organisms. Am J Infect Control. maio de 2021;49(5):653–4.
Cano-Martín E, Portillo-Calderón I, Pérez-Palacios P, Navarro-Marí JM, Fernández-Sierra MA, Gutiérrez-Fernández J. A Study in a Regional Hospital of a Mid-Sized Spanish City Indicates a Major Increase in Infection/Colonization by Carbapenem-Resistant Bacteria, Coinciding with the COVID-19 Pandemic. Antibiotics (Basel). 18 de setembro de 2021;10(9):1127.
Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Azzam Lopez A, Diez-Remesal Y, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis. março de 2021;40(3):495–502.
Wang L, Amin AK, Khanna P, Aali A, McGregor A, Bassett P, et al. An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. Journal of Antimicrobial Chemotherapy. 1o de março de 2021;76(3):796–803.
Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan). 25 de abril de 2021;13(1):5.
Bogossian EG, Taccone FS, Izzi A, Yin N, Garufi A, Hublet S, et al. The Acquisition of Multidrug-Resistant Bacteria in Patients Admitted to COVID-19 Intensive Care Units: A Monocentric Retrospective Case Control Study. Microorganisms. 19 de novembro de 2020;8(11):E1821.
Secretaria de Estado da Saúde do Paraná (SESA).Resolução 096/2018.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
